Vertex Pharmaceuticals/Yale Research Team Uses Gene Knockout Mice To Establish Role Of Caspase-9 In Neuronal Cell Death Pathway

-9 function through a gene-knockout experiment, and illustrates how Vertex approaches functional genomics as part of an integrated discovery platform," said Dr. Joshua Boger, Chairman, President, and CEO of Vertex. "This research clarifying the relationship between caspases and their activity in body tissues greatly increases our understanding of which caspases are appropriate targets for drug discovery."

Vertex Pharmaceuticals has an established track record of scientific innovation and is a leader in caspase research. Previously, Vertex and Yale/HHMI researchers were the first to describe the biochemical and physiological effects of the ICE (Caspase-1) enzyme through a gene knockout mouse experiment, and Vertex researchers were the first to elucidate the 3-dimensional atomic structure of ICE. Additionally, Dr. Keisuke Kuida, together with colleagues Dr. Richard Flavell and Dr. Pasko Rakic, reported the first Caspase-3 (CPP32) gene knockout mouse, and Vertex researchers have solved the structure of the Caspase-3 enzyme. Vertex and partner Hoechst Marion Roussel plan to begin Phase I clinical trials of VX-740, an inhibitor of ICE targeting inflammatory diseases, later in 1998. Vertex has a research program directed at developing novel, orally administered inhibitors of different targets in the caspase family with potential in the treatment of stroke, Alzheimer's and Parkinson's diseases, myocardial ischemia and other indications.

The contributors to the Cell paper include Dr. Richard Flavell, a Howard Hughes Investigator, and Drs. Pasko Rakic, Tarik Haydar, and Chia-Yi Kuan, all of the Yale University School of Medicine; Drs. Choji Taya and Hajime Karasuyama, both of the Tokyo Metropolitan Institute of Medical Science; and Drs. Keisuke Kuida, Yong Gu and Michael Su, all of Vertex.

Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) is engaged in the discovery, development and commercialization of novel, small molecule pharmaceuticals for the treatme

Contact: Michael Partridge
(617) 577-6108
Vertex Pharmaceuticals

Page: 1 2 3 4

Related biology news :

1. Research Findings Suggest Potent, Broad-Spectrum Antiviral Activity For Vertexs Investigational IMPDH Inhibitor VX-497
2. Phase III Results Suggest Potent Antiviral Activity For Vertex And Glaxo Wellcomes Second-Generation HIV Protease Inhibitor Agenerase TM
3. Vertex Researchers Report Three-Dimensional Atomic Structure Of JNK3 Enzyme; Report In Structure
4. Vertex Pharmaceuticals Researchers Report Three-Dimensional Structure Of Hepatitis C Helicase Enzyme; Report In Structure
5. Researchers determine genetic cause of Timothy syndrome
6. Researchers find color sensitive atomic switch in bacteria
7. Schepens Eye Research Institute receives Roadmap grant to develop center for curing eye diseases
8. Researchers identify protein promoting vascular tumor growth
9. Researchers devise potent new tools to curb ivory poaching
10. Researchers create nanotubes that change colors, form nanocarpet and kill bacteria
11. Researchers ID chlorophyll-regulating gene

Post Your Comments:

(Date:8/31/2018)... BARBARA, Calif. (PRWEB) , ... August 30, 2018 , ... ... optimization firm for the life sciences and healthcare industries, has received the 2018 Services ... management. The award was presented by Box SVP of Business Development and Platform Sales, ...
(Date:8/29/2018)... ... August 28, 2018 , ... Johanna Dwyer, founder ... recognizes women of excellence in the field of intellectual property, and named Daniela ... Women in IP Award aims to encourage and support women in their pursuit ...
(Date:8/29/2018)... (PRWEB) , ... August 29, ... ... study validates first non-invasive technology to identify specific chromosomal abnormalities using morphological ... Ovation Fertility and Australia-based Life Whisperer suggests that ...
Breaking Biology News(10 mins):
(Date:8/26/2018)... ... August 24, 2018 , ... ExoCoBio Inc., based ... relieves atopic dermatitis and inhibits a variety of inflammatory targets in the journal ... symptoms of mice having severe atopic dermatitis were significantly improved after administration of ...
(Date:8/21/2018)... ... August 21, 2018 , ... ... company specializing in medical device compliance and commercialization, has just released a ... , Written and presented by Dr. Mario Kossmann, ESEP at the 28th ...
(Date:8/17/2018)... Kan. (PRWEB) , ... August 16, 2018 , ... ... research organization (CRO) is pleased to announce the expansion of their team. Dr. ... was hired to launch an innovative large molecule LC-MS/MS group that will specialize ...
(Date:8/14/2018)... ... August 13, 2018 , ... Labconco Corporation manufactures ... safety cabinets. In addition, Labconco produces other lab equipment, such as glassware washers ... to quality and consistency in design and manufacturing. , Through this webinar, ...
Breaking Biology Technology:
Cached News: